DGD-1202

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameDGD-1202
Drug Alias NameDisruptinEGFR inhibitor (DGD Pharmaceuticals)DGD-1202
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsLung NeoplasmsHead and Neck NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Michigan
China Registration ClassN/A

Develop Information

Active CompaniesDGD Pharmaceuticals Corp
Inactive CompaniesUniversity Of Michigan
Active IndicationsLung NeoplasmsHead and Neck Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A